Trial · NCT01587898
Results by group1,505
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 1,505
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Modeled Hgb Change From Baseline Over 4 Weeks of Treatment | Placebo | -0.148 | Standard Deviation 0.1925 | gram per decilitre (g/dL) | |
| Modeled Hgb Change From Baseline Over 4 Weeks of Treatment | GSK1278863, 0.5 mg | 0.132 | Standard Deviation 0.2200 | gram per decilitre (g/dL) | |
| Modeled Hgb Change From Baseline Over 4 Weeks of Treatment | GSK1278863, 2 mg | 0.463 | Standard Deviation 0.2173 | gram per decilitre (g/dL) | |
| Modeled Hgb Change From Baseline Over 4 Weeks of Treatment | GSK1278863, 5 mg | 1.010 | Standard Deviation 0.2614 | gram per decilitre (g/dL) | |
| Model-Adjusted Maximum Hgb Changes Over 4 Weeks | Placebo | 0.153 | Standard Error 0.1476 | g/dL | |
| Model-Adjusted Maximum Hgb Changes Over 4 Weeks | GSK1278863, 0.5 mg | 0.137 | Standard Error 0.1609 | g/dL | |
| Model-Adjusted Maximum Hgb Changes Over 4 Weeks | GSK1278863, 2 mg | 0.474 | Standard Error 0.1532 | g/dL | |
| Model-Adjusted Maximum Hgb Changes Over 4 Weeks | GSK1278863, 5 mg | 1.069 | Standard Error 0.1527 | g/dL | |
| Number of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb | Placebo | Decrease/increase of < 0.5 g/dL | 16 | Participants | |
| Number of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb | GSK1278863, 0.5 mg | Decrease/increase of < 0.5 g/dL | 12 | Participants | |
| Number of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb | GSK1278863, 2 mg | Decrease/increase of < 0.5 g/dL | 12 | Participants | |
| Number of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb | GSK1278863, 5 mg | Decrease/increase of < 0.5 g/dL | 4 | Participants | |
| Number of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb | Placebo | Increase of >=0.5 g/dL | 3 | Participants | |
| Number of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb | GSK1278863, 0.5 mg | Increase of >=0.5 g/dL | 4 | Participants | |
| Number of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb | GSK1278863, 2 mg | Increase of >=0.5 g/dL | 6 | Participants | |
| Number of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb | GSK1278863, 5 mg | Increase of >=0.5 g/dL | 14 | Participants | |
| Number of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb | Placebo | Increase of >=1 g/dL | 1 | Participants | |
| Number of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb | GSK1278863, 0.5 mg | Increase of >=1 g/dL | 1 | Participants | |
| Number of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb | GSK1278863, 2 mg | Increase of >=1 g/dL | 2 | Participants | |
| Number of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb | GSK1278863, 5 mg | Increase of >=1 g/dL | 9 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01587898/results